RADIOIMMUNO POSITRON EMISSION TOMOGRAPHY WITH MONOCLONAL-ANTIBODIES - A NEW APPROACH TO QUANTIFYING INVIVO TUMOR CONCENTRATION AND BIODISTRIBUTION FOR RADIOIMMUNOTHERAPY

被引：34

作者：

WESTERA, G

REIST, HW

BUCHEGGER, F

HEUSSER, CH

HARDMAN, N

PFEIFFER, A

SHARMA, HL

VONSCHULTHESS, GK

MACH, JP

机构：

[1] Department of Radiology, Clinic of Nuclear Medicine, University Hospital Zürich, Zürich

[2] Paul Scherrer Institut, Villigen-PSl

[3] Institute of Biochemistry, University of Lausanne, Epalinges, Lausanne

[4] Ciba-Geigy AG, Basel

[5] Department of Medical Biophysics, University of Manchester

来源：

NUCLEAR MEDICINE COMMUNICATIONS | 1991年 / 12卷 / 05期

关键词：

D O I：

10.1097/00006231-199105000-00007

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Radioimmunodetection of tumours with monoclonal antibodies is becoming an established procedure. Positron emission tomography (PET) shows better resolution than normal gamma camera single photon emission tomography and can provide more precise quantitative data. Thus, in the present study, these powerful methods have been combined to perform radioimmuno PET (RI-PET). Monoclonal antibodies directed against carcinoembryonic antigen (CEA) an IgG, its F(ab')2 and a mouse-human chimeric IgG derived from it were labelled with I-124, a positron-emitting radionuclide with a convenient physical half-life of four days. Mice, xenografted with a CEA-producing human colon carcinoma, were injected with the I-124-MAb and the tumours were visualized using PET. The concentrations of I-124 in tumour and normal tissue were determined by both PET and direct radioactivity counting of the dissected animals, with very good agreement. To allow PET quantification, a procedure was established to account for the presence of radioactivity during the absorption correction measurement (transmission scan). Comparison of PET and tissue counting indicates that this novel combination of radioimmunolocalization and PET (RI-PET) will provide, in addition to more precise diagnosis, more accurate radiation dosimetry for radioimmunotherapy.

引用

页码：429 / 437

页数：9

共 15 条

[1]

Mach J.P., Buchegger F., Forni M., Ritschard J., Berche C., Lumbroso J.-D., Schreyer M., Girardet C., Accolla R.S., Carrel S., Use of radiolabeled monoclonal anti-CEA antibodies for the detection of human colon carcinomas by external photoscanning and tomography, Immunol Today, 2, pp. 239-249, (1981)

[2]

Larson S.M., Carrasquillo J.A., Krohn K.A., Brown J.P., McGuffin R.W., Ferens J.M., Graham M.M., Hill L.D., Beaumier P.L., Hellstrom K.E., Hellstrom I., Localization of131I-labeled P97-specific Fab fragments in human melanoma as a basis for radiotherapy, J Clin Invest, 72, pp. 2101-2114, (1983)

[3]

Siccardi A.G., Tumor immunoscintigraphy by means of radiolabeled monoclonal antibodies: Multicenter studies of the Italian national research council - Special project biomedical engineering, Cancer Res, 80, pp. 889s-903s, (1990)

[4]

Granowska M., Britton K.E., Shepherd J.H., Nimmon C.C., Mather S., Ward B., Osborne R.J., Slevin M.L., A prospective study of123I-labeled monoclonal antibody imaging in ovarian cancer, J Clin Oncol, 4, pp. 730-736, (1986)

[5]

Goldenberg D.M., Goldenberg H., Sharkey R.M., Higginbotham-Ford E., Lee R.E., Swayne L.C., Burger K., Tsai D., Horowitz J.A., Hall T.C., Pinsky C.M., Hansen H.J., Clinical studies of cancer radioimmunodetection with carcinoembryonic antigen monoclonal antibody fragments labeled with 123I or99Tcm, Cancer Res, 80, pp. 909s-921s, (1990)

[6]

Macklis R.M., Kinsey B.M., Kassis A.I., Ferrara J.L., Atcher R.W., Hines J.J., Coleman C.N., Adelstein S.J., Burakoff S.J., Radioimmunotherapy with alpha-particle-emitting immuno- conjugates, Science, 240, pp. 1024-1026, (1988)

[7]

Smith A., Groscurth P., Waibel R., Westera G., Stahel R.A., Imaging and therapy of small cell carcinoma xenografts using131I-labeled monoclonal antibody SWA11, Cancer Res, 80, pp. 980s-984s, (1990)

[8]

Buchegger F., Pѐlegrin A., Deleloye B., Bischof-Delaloye A., Mach J.-P., Iodine-131-labeled MAb F(ab')2fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice, J Nucl Med, 31, pp. 1035-1044, (1990)

[9]

Buchsbaum D., Ten Haken R.K., Heidorn D.B., Lawrence T.S., Glatfelter A.A., Terry V.H., Guilbault D.M., Steplewski Z., Lichter A.S., A comparison of131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts, Int J Rad Oncol Biol Phys, 18, pp. 1033-1041, (1990)

[10]

Humm J.L., Cobb L.M., Nonuniformity of tumor dose in radioimmunotherapy, J Nucl Med, 31, pp. 75-83, (1990)

← 1 2 →